An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

This is an open-label, single-arm study to investigate the efficacy and safety signals of JWCAR201 amongst subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Trial Details

NCT ID
NCT06517004
Phase
PHASE1
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • JWCAR201
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Voluntarily willing to participate in the study and sign the written informed consent form
  • Histologically confirmed diffuse large B-cell lymphoma (DLBCL) with immunohistochemistry (IHC) CD20-positive
  • Patients must be priorly treated by Anthracyclines and anti-CD20-targeted regimens, and must be refractory or relapsed to at least ≥2 treatment lin…
  • At least one measurable lesion by CT or PET per Lugano criteria

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →